Evidence map›Paper›PMID 35855850›Full record

ArticleDisease markers2022

High Expression of

Yan Chen, Min Zhou, Xuyu Gu, Longfei Wang, Cailian Wang

Open access · hybridAbstract read
In one paragraph

Article in Disease markers, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
1.1field-weighted citation impact, top 23% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed, 7 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors at 1 institution in 1 country.

Yan ChenDepartment of Oncology, Zhongda Hospital, School of Medicine, Southeast University, Nanjing 210009, China.
Min ZhouDepartment of Oncology, Zhongda Hospital, School of Medicine, Southeast University, Nanjing 210009, China.ORCID https://orcid.org/0000-0003-2477-4513
Xuyu GuDepartment of Oncology, Zhongda Hospital, School of Medicine, Southeast University, Nanjing 210009, China.
Longfei WangDepartment of Pathology, Zhongda Hospital, Southeast University, Nanjing 210009, China.
Cailian WangDepartment of Oncology, Zhongda Hospital, School of Medicine, Southeast University, Nanjing 210009, China.ORCID https://orcid.org/0000-0002-1728-3137
Zhongda Hospital Southeast University · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Background: Lung adenocarcinoma (LUAD) has been recognized as one of the commonest aggressive malignant tumors occurring in humans. The transforming acidic coiled-coil-containing protein 3 ( Methods: Premised on the data accessed from The Cancer Genome Atlas- (TCGA-) LUAD, we carried out bioinformatics analysis. The Results: The outcomes illustrated that Conclusion: The findings from this research offer robust proof that the expression of

Indexed as

Adenocarcinoma of LungCarcinoma, Non-Small-Cell LungLung NeoplasmsMicrotubule-Associated ProteinsCell Cycle ProteinsHumansPrognosisCell Cycle ProteinsMicrotubule-Associated ProteinsTACC3 protein, human

Identifiers

PMID35855850
PMCPMC9288335
OpenAlexW4284959767

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.